RingConn ends blood pressure beta as next phase comes into focus
RingConn is shutting down its Blood Pressure Insights Beta at the end of March, with users already receiving confirmation inside the app. The move comes six months after the feature first appeared and raises questions about what happens next.
There are a few ways to read this, and none of them point to the feature simply disappearing.
Beta is ending but not necessarily the feature
The message being sent to users is quite direct. The beta ends on March 31st and the feature will no longer be available in its current form. That sounds abrupt, but it is actually quite typical for health features that rely on calibration and algorithm tuning.
Blood pressure estimation on wearables is not a straightforward sensor readout. It relies on indirect signals, usually pulse transit time or similar metrics, combined with calibration data. That means beta periods are often used to collect large datasets and refine models before a wider rollout.
From that perspective, ending the beta can just mean one thing. The data collection phase is done.
Timing lines up with a wider rollout
The October 2025 start date for the beta gives it a reasonable window to gather enough variation across users, conditions and daily routines. Shutting it down at the end of March creates a clean break before whatever comes next. That could be a reworked version of the feature, possibly with tighter calibration requirements or improved consistency.
It is also worth noting that companies rarely keep a beta running indefinitely if they plan to ship the feature more broadly. At some point, they need to lock the model and move to a production version.
Where does this leave Gen 2 devices
But who actually gets the feature. This is where things get less clear. If blood pressure was already running on existing hardware during the beta, that suggests Gen 2 devices are technically capable of supporting it.
The question is whether RingConn wants to keep it there.
There are two competing incentives. On one hand, rolling it out to existing users builds trust and adds value to devices already in the wild. On the other hand, blood pressure is a headline feature that can help sell new hardware.
A middle ground is possible. The company could bring a basic version to Gen 2 while reserving a more refined or easier to use implementation for newer devices.
Gen 3 already points to the answer
The strongest clue comes from the upcoming Gen 3 ring. That device is already being positioned with blood pressure tracking as one of its key capabilities.
That makes it unlikely the feature is being abandoned. It is more likely being held back for a more controlled launch.
There is also a practical angle. If Gen 3 includes changes to sensor layout or signal processing, the algorithms developed during the beta might perform better on that hardware. In that case, RingConn may choose to align the full rollout with the new device.
The most likely scenario is a relaunch rather than a disappearance. The beta ends, the feature goes away temporarily, and then returns in a more polished form.
That could happen as a software update for existing users, or it could arrive alongside Gen 3 as a flagship capability and then trickle down later. Either way, it probably won’t be long before we find out. But to us it looks like RingConn has gathered what it needed and is now preparing the next step.
Subscribe to our monthly newsletter! Check out our YouTube channel.
And of course, you can follow Gadgets & Wearables on Google News and add us as a preferred source to get our expert news, reviews, and opinion in your feeds.
